ACAD
ACADIA Pharmaceuticals Inc. NASDAQ Listed May 27, 2004$21.62
+0.09%
vs $21.60
Mkt Cap $3.7B
52w Low $19.69
22.3% of range
52w High $28.35
50d MA $21.70
200d MA $23.29
P/E (TTM)
9.4x
EV/EBITDA
20.8x
P/B
3.0x
Debt/Equity
0.0x
ROE
31.9%
P/FCF
35.2x
RSI (14)
49.50
ATR (14)
$0.61
Beta
0.83
50d MA
$21.70
200d MA
$23.29
Avg Volume
1.5M
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
12830 El Camino Real · San Diego, CA 92130 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | 0.04 | 0.02 | -50.0% | 21.48 | +1.9% | +5.0% | -0.7% | -2.7% | -0.4% | +2.1% | — |
| Feb 25, 2026 | AMC | 0.14 | 1.60 | +1067.9% | 24.97 | -5.3% | -1.3% | -0.3% | -7.1% | -1.4% | +4.0% | — |
| Nov 5, 2025 | AMC | 0.14 | 0.26 | +85.7% | 22.33 | +5.6% | -3.0% | +4.2% | -1.6% | +6.8% | +1.7% | — |
| Aug 6, 2025 | AMC | 0.14 | 0.16 | +14.3% | 23.80 | +1.1% | +2.5% | +0.8% | +0.9% | +2.5% | -1.3% | — |
| May 7, 2025 | AMC | 0.10 | 0.11 | +10.0% | 14.81 | -0.6% | +14.3% | +3.0% | +0.5% | -1.8% | -0.2% | — |
| Feb 26, 2025 | AMC | 0.13 | 0.17 | +30.8% | 19.00 | +2.3% | +1.8% | +1.3% | -7.3% | +0.6% | -1.0% | — |
| Nov 6, 2024 | AMC | 0.14 | 0.20 | +42.9% | 15.79 | -0.6% | +8.9% | +2.7% | +3.5% | -1.9% | -1.9% | — |
| Aug 6, 2024 | AMC | 0.18 | 0.20 | +11.1% | 18.85 | -18.3% | -19.5% | +3.6% | -0.6% | -2.2% | +2.9% | — |
| May 8, 2024 | AMC | 0.05 | 0.10 | +100.0% | 17.13 | +2.2% | -11.2% | +0.3% | -0.5% | -2.1% | +1.7% | — |
| Feb 27, 2024 | AMC | 0.30 | 0.28 | -6.7% | 26.36 | -6.5% | -9.9% | -2.1% | +3.3% | -1.1% | +0.3% | — |
| Nov 2, 2023 | AMC | -0.43 | -0.40 | +7.0% | 22.99 | +4.4% | +4.7% | -0.4% | -2.0% | -1.3% | -5.1% | — |
| Aug 2, 2023 | AMC | -0.12 | 0.01 | +108.3% | 29.20 | -4.2% | -6.8% | -0.0% | -1.4% | -0.3% | -0.5% | — |
| May 8, 2023 | AMC | -0.21 | -0.27 | -28.6% | 21.55 | +0.2% | -0.6% | +1.0% | -1.4% | +0.6% | +3.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25 | BofA Securities | Upgrade | Neutral → Buy | — | $20.96 | $21.40 | +2.1% | +5.0% | -2.5% | -3.4% | +1.5% | +5.6% |
| Mar 4 | JP Morgan | Maintains | Overweight → Overweight | — | $22.50 | $23.05 | +2.4% | +4.0% | -4.2% | -1.1% | +1.9% | -0.2% |
| Feb 26 | Citizens | Maintains | Market Outperform → Market Outperform | — | $24.97 | $23.64 | -5.3% | -1.3% | -0.3% | -7.1% | -1.4% | +4.0% |
| Feb 26 | TD Cowen | Maintains | Buy → Buy | — | $24.97 | $23.64 | -5.3% | -1.3% | -0.3% | -7.1% | -1.4% | +4.0% |
| Feb 26 | RBC Capital | Maintains | Outperform → Outperform | — | $24.97 | $23.64 | -5.3% | -1.3% | -0.3% | -7.1% | -1.4% | +4.0% |
| Feb 26 | Stifel | Maintains | Hold → Hold | — | $24.97 | $23.64 | -5.3% | -1.3% | -0.3% | -7.1% | -1.4% | +4.0% |
| Feb 23 | Mizuho | Upgrade | Neutral → Outperform | — | $23.99 | $24.78 | +3.3% | +3.1% | -0.6% | +1.5% | -1.3% | -0.3% |
| Feb 6 | Oppenheimer | Maintains | Perform → Perform | — | $23.46 | $24.04 | +2.5% | +0.4% | -1.4% | -2.2% | -1.0% | -3.8% |
| Feb 3 | RBC Capital | Maintains | Outperform → Outperform | — | $26.13 | $25.69 | -1.7% | -5.2% | -2.1% | -3.2% | +0.4% | -1.4% |
| Feb 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.13 | $25.69 | -1.7% | -5.2% | -2.1% | -3.2% | +0.4% | -1.4% |
| Feb 3 | Citizens | Maintains | Market Outperform → Market Outperform | — | $26.13 | $25.69 | -1.7% | -5.2% | -2.1% | -3.2% | +0.4% | -1.4% |
| Jan 6 | Citigroup | Maintains | Buy → Buy | — | $26.15 | $26.50 | +1.3% | +3.0% | +1.8% | -1.9% | -0.5% | -0.7% |
| Jan 6 | UBS | Maintains | Buy → Buy | — | $26.15 | $26.50 | +1.3% | +3.0% | +1.8% | -1.9% | -0.5% | -0.7% |
| Dec 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.15 | $27.18 | +0.1% | +0.4% | -1.7% | +0.5% | -1.2% | +2.1% |
| Dec 11 | Stifel | Maintains | Hold → Hold | — | $26.81 | $26.67 | -0.5% | -0.5% | +1.8% | +0.4% | -1.7% | +0.5% |
| Dec 2 | Mizuho | Maintains | Neutral → Neutral | — | $24.85 | $25.24 | +1.6% | +2.3% | +1.8% | +2.6% | +3.4% | -2.5% |
| Nov 17 | JP Morgan | Maintains | Overweight → Overweight | — | $24.02 | $23.65 | -1.5% | -0.0% | -0.9% | -2.9% | -0.9% | +2.9% |
| Nov 6 | Needham | Maintains | Buy → Buy | — | $22.33 | $23.58 | +5.6% | -3.0% | +4.2% | -1.6% | +6.8% | +1.7% |
| Nov 6 | RBC Capital | Maintains | Outperform → Outperform | — | $22.33 | $23.58 | +5.6% | -3.0% | +4.2% | -1.6% | +6.8% | +1.7% |
| Sep 29 | JP Morgan | Maintains | Overweight → Overweight | — | $21.05 | $21.27 | +1.0% | +1.3% | +0.1% | -0.5% | +0.7% | +2.0% |
| Sep 24 | Needham | Maintains | Buy → Buy | — | $23.60 | $20.82 | -11.8% | -9.9% | -0.2% | -0.8% | +1.3% | +0.1% |
| Sep 11 | TD Cowen | Maintains | Buy → Buy | — | $23.80 | $24.16 | +1.5% | +1.7% | -2.4% | +4.5% | -2.9% | +1.0% |
| Sep 9 | UBS | Maintains | Buy → Buy | — | $25.39 | $25.54 | +0.6% | -2.2% | -4.2% | +1.7% | -2.4% | +4.5% |
| Aug 8 | UBS | Maintains | Buy → Buy | — | $24.40 | $24.40 | +0.0% | +0.8% | +0.9% | +2.5% | -1.3% | -2.4% |
| Aug 7 | Goldman Sachs | Maintains | Sell → Sell | — | $23.80 | $24.06 | +1.1% | +2.5% | +0.8% | +0.9% | +2.5% | -1.3% |
| Aug 7 | Mizuho | Maintains | Neutral → Neutral | — | $23.80 | $24.06 | +1.1% | +2.5% | +0.8% | +0.9% | +2.5% | -1.3% |
| Aug 7 | BofA Securities | Maintains | Neutral → Neutral | — | $23.80 | $24.06 | +1.1% | +2.5% | +0.8% | +0.9% | +2.5% | -1.3% |
| Aug 7 | RBC Capital | Maintains | Outperform → Outperform | — | $23.80 | $24.06 | +1.1% | +2.5% | +0.8% | +0.9% | +2.5% | -1.3% |
| Aug 7 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $23.80 | $24.06 | +1.1% | +2.5% | +0.8% | +0.9% | +2.5% | -1.3% |
| Jul 24 | JP Morgan | Maintains | Overweight → Overweight | — | $23.27 | $23.00 | -1.2% | -0.9% | +0.9% | -2.7% | +0.0% | +4.0% |
| Jun 27 | UBS | Maintains | Buy → Buy | — | $22.21 | $22.18 | -0.1% | -0.4% | -2.5% | -1.0% | -0.6% | -1.4% |
| Jun 26 | Needham | Maintains | Buy → Buy | — | $22.50 | $22.56 | +0.3% | -1.3% | -0.4% | -2.5% | -1.0% | -0.6% |
| Jun 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.50 | $22.56 | +0.3% | -1.3% | -0.4% | -2.5% | -1.0% | -0.6% |
| Jun 26 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $22.50 | $22.56 | +0.3% | -1.3% | -0.4% | -2.5% | -1.0% | -0.6% |
| Jun 26 | Oppenheimer | Maintains | Perform → Perform | — | $22.50 | $22.56 | +0.3% | -1.3% | -0.4% | -2.5% | -1.0% | -0.6% |
| Jun 23 | RBC Capital | Maintains | Outperform → Outperform | — | $22.71 | $23.04 | +1.5% | -1.0% | -0.3% | +0.4% | -1.3% | -0.4% |
| Jun 6 | JP Morgan | Maintains | Overweight → Overweight | — | $21.34 | $21.53 | +0.9% | +3.0% | +1.5% | -0.4% | +0.5% | -2.5% |
| Jun 5 | BofA Securities | Maintains | Neutral → Neutral | — | $21.77 | $21.61 | -0.7% | -2.0% | +3.0% | +1.5% | -0.4% | +0.5% |
| May 21 | Deutsche Bank | Upgrade | Hold → Buy | — | $21.69 | $22.24 | +2.5% | +0.7% | -1.4% | +2.0% | +1.0% | -0.8% |
| May 20 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $21.99 | $21.85 | -0.6% | -1.4% | +0.7% | -1.4% | +2.0% | +1.0% |
| May 19 | RBC Capital | Maintains | Outperform → Outperform | — | $22.26 | $22.30 | +0.2% | -1.2% | -1.4% | +0.7% | -1.4% | +2.0% |
| May 19 | Baird | Maintains | Outperform → Outperform | — | $22.26 | $22.30 | +0.2% | -1.2% | -1.4% | +0.7% | -1.4% | +2.0% |
| May 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.26 | $22.30 | +0.2% | -1.2% | -1.4% | +0.7% | -1.4% | +2.0% |
| May 19 | Mizuho | Maintains | Neutral → Neutral | — | $22.26 | $22.30 | +0.2% | -1.2% | -1.4% | +0.7% | -1.4% | +2.0% |
| May 19 | Needham | Maintains | Buy → Buy | — | $22.26 | $22.30 | +0.2% | -1.2% | -1.4% | +0.7% | -1.4% | +2.0% |
| May 19 | BMO Capital | Maintains | Outperform → Outperform | — | $22.26 | $22.30 | +0.2% | -1.2% | -1.4% | +0.7% | -1.4% | +2.0% |
| May 16 | JP Morgan | Maintains | Overweight → Overweight | — | $17.60 | $18.37 | +4.4% | +26.5% | -1.2% | -1.4% | +0.7% | -1.4% |
| May 8 | Deutsche Bank | Maintains | Hold → Hold | — | $14.81 | $14.72 | -0.6% | +14.3% | +3.0% | +0.5% | -1.8% | -0.2% |
| Apr 28 | UBS | Maintains | Buy → Buy | — | $14.73 | $14.80 | +0.5% | -0.5% | -1.6% | +1.2% | -0.2% | +2.3% |
| Apr 17 | BofA Securities | Maintains | Neutral → Neutral | — | $14.57 | $14.47 | -0.7% | +1.1% | -2.4% | -0.2% | +1.9% | +1.4% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 26, 2026 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 5,401 | $21.18 | $114K | 24,509 | +2.08% | +2.58% |
| May 4, 2026 | Kihara James | PRINCIPAL ACCOUNTING OFFICER | Sell | 1,332 | $21.79 | $29K | 29,129 | -3.89% | -0.37% |
| May 4, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 3,506 | $21.79 | $76K | 66,145 | -3.89% | -0.37% |
8-K · 5.02
!!! Very High
ACADIA Pharmaceuticals Inc. -- 8-K 5.02: Executive Change
May 29
8-K · 5.02
!!! Very High
ACADIA Pharmaceuticals Inc. -- 8-K 5.02: Executive Change
ACADIA Pharmaceuticals appointed Thompson as a director, potentially signaling new leadership perspective and governance strengthening for the biopharmaceutical company's board oversight.
May 1
8-K · 5.02
!!! Very High
Acadia Pharmaceuticals Inc. -- 8-K 5.02: Executive Change
Jonathan M. Poole has joined Acadia Pharmaceuticals' board as a Class II director, expanding the company's governance structure and potentially bringing new expertise to guide strategic decisions.
Mar 5
8-K
Acadia Pharmaceuticals Inc. -- 8-K Filing
Acadia Pharmaceuticals surpassed $1 billion in annual revenue for the first time in 2025, demonstrating strong operational growth and market success across its pharmaceutical portfolio.
Feb 25
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Portfolio Management Llc | 8,671,645 | $193M | New | Mar 2026 |
| 2 | Rtw Investments, Lp | 7,144,524 | $159M | — | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 5,661,400 | $126M | New | Mar 2026 |
| 4 | First Trust Advisors Lp | 3,343,868 | $74M | Added | Mar 2026 |
| 5 | Morgan Stanley | 2,283,948 | $61M | Reduced | Dec 2025 |
| 6 | Point72 Asset Management | 2,577,916 | $57M | Reduced | Mar 2026 |
| 7 | Braidwell Lp | 2,032,021 | $54M | Reduced | Dec 2025 |
| 8 | Pictet Asset Management Holding Sa | 1,547,103 | $41M | Added | Dec 2025 |
| 9 | Renaissance Technologies Llc | 1,724,196 | $38M | Added | Mar 2026 |
| 10 | Arrowstreet Capital, Limited Partnership | 1,569,491 | $35M | Added | Mar 2026 |
| 11 | Bank Of America Corp /de/ | 1,553,770 | $35M | Added | Mar 2026 |
| 12 | Artisan Partners Limited Partnership | 1,331,813 | $30M | New | Mar 2026 |
| 13 | Northern Trust Corp | 1,272,611 | $28M | Added | Mar 2026 |
| 14 | Nuveen, Llc | 1,036,987 | $23M | Reduced | Mar 2026 |
| 15 | Rockefeller Capital Management L.p. | 1,027,357 | $23M | Reduced | Mar 2026 |
| 16 | Allspring Global Investments Holdings, Llc | 954,855 | $21M | Added | Mar 2026 |
| 17 | Qube Research & Technologies Ltd | 950,299 | $21M | Reduced | Mar 2026 |
| 18 | Principal Financial Group Inc | 745,356 | $20M | Added | Dec 2025 |
| 19 | Invesco Ltd. | 836,510 | $19M | Reduced | Mar 2026 |
| 20 | Two Sigma Investments, Lp | 775,121 | $17M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$3.70B
Enterprise Value
$2.89B
P/E (TTM)
9.44x
Forward P/E
48.78x
PEG Ratio
0.17x
P/B
2.98x
P/S
3.46x
P/FCF
35.23x
EV/EBITDA
20.77x
Shares Out
171.4M
Financials (TTM)
Revenue
$1.07B
Net Income
$391.0M
EBITDA
$138.9M
Free Cash Flow
$105.1M
Op Cash Flow
$109.8M
EPS Basic
$2.32
EPS Diluted
$2.29
EPS Forward
$0.44
Gross Margin
91.7%
Op Margin
9.8%
Net Margin
36.5%
Balance Sheet
Total Assets
$1.56B
Total Liab.
$336.8M
Total Equity
$1.23B
Cash
$819.7M
LT Debt
$0
Book Value/Sh
$7.25
Debt/Equity
0.04x
Current Ratio
3.83
Quick Ratio
3.71
Returns & Growth
ROE
31.9%
ROA
25.0%
ROIC
8.1%
Rev Growth YoY
+11.9%
EPS Growth YoY
+69.3%
Price Returns
2W
-1.9%
1M
-3.5%
3M
-11.8%
6M
-13.5%
12M
+0.4%
Technicals
52W High
$28.35
52W Low
$19.69
50d MA
$21.70
200d MA
$23.29
RSI (14)
49.50
ATR (14)
$0.61
Beta
0.83
Avg Volume
1.5M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$34.78
High
$40.00
Low
$29.00
Median
$35.00
Data updated apr 24, 2026 10:23am
· Source: financialmodelingprep.com